Evaluation of the relationship between adjusted ischemia-modified albumin and the presence and severity of peripheral artery disease

Abstract

Objectives

Albumin undergoes structural changes under ischemia and oxidative stress, turning into ischemia-modified albumin (IMA). It has been proposed as an early biomarker for various diseases associated with ischemia. We aimed to investigate the relationship between serum IMA and peripheral artery disease (PAD) and whether it is a risk marker for the severity of PAD.

Methods

This prospective case-control study included 100 patients with lower extremity PAD and 50 volunteers without. Patients with resting pain, ulcer, and gangrene were excluded from the study. Patients with PAD included in the study were divided into two groups as mild claudication and moderate-severe claudication. Adjusted-IMA levels were calculated according to the median albumin values of the groups. The basic clinical features and laboratory findings of the participants were recorded and compared. Possible risk factors for presence and severity of PAD and IMA levels were examined by logistic regression and receiver-operating characteristic (ROC) curve analyses.

Results

IMA and adjusted-IMA levels were significantly higher in the PAD group (p < 0.001, p < 0.001, respectively). IMA and adjusted-IMA levels were significantly higher in PAD group 2, which had moderate-to-severe claudication and more pronounced ischemic symptoms (p < 0.001, p < 0.001, respectively). Advanced age, presence of hypertension, smoking, low albumin levels, and high adjusted-IMA levels were independent predictors of PAD. There was a negative high correlation between adjusted-IMA levels and ABI (r: −0.666, p < 0.001, Spearman’s correlation). ROC curve analysis demonstrated that adjusted-IMA cut-off values of 0.802 or above could predict presence and severity of peripheral artery disease with 70% sensitivity and 78% specificity (AUC: 0.825, 95% CI: 0.758–0.893, log rank p: 0.000).

Conclusion

We determinated that increased adjusted-IMA levels were a predictors of the presence and severity of PAD. In addition, adjusted-IMA values can be a valuable marker in the follow-up of clinical severity of PAD.

Keywords

Peripheral arterial disease ischemia-modified albumin biomarker

Get full access to this article

View all access options for this article.

References

Engin

Cihan

Güvenç

. Is it possible to predict the complexity of peripheral artery disease with atherogenic index? Vascular 2020; 28(5): 513–519.

Hirsch

Haskal

Hertzer

, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American association for vascular surgery/society for vascular sur. Circulation 2006; 113(11): 463–654.

Hamburg

Creager

. Pathophysiology of intermittent claudication in peripheral artery disease. Circ J 2017; 81(3): 281–289.

Süleymanoğlu

Burak

Gümüşdağ

, et al. Assessment of the relation between C-reactive protein to albumin ratio and the severity and complexity of peripheral arterial disease. Vascular 2020; 28(6): 731–738.

Siti

Kamisah

Kamsiah

. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 2015; 71: 40–56.

Bar-Or

Lau

Winkler

. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19(4): 311–315.

Shevtsova

Gordiienko

Tkachenko

, et al. Ischemia-modified albumin: origins and clinical implications. Dis Markers 2021; 2021: 9945424.

Seneş

Kazan

Coşkun

, et al. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007; 44: 43–47.

Gunduz

Turkmen

Turedi

, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 2009; 16: 539–543.

10.

Özsin

Balci

Sanri

, et al. Levels of ischemia: modified albumin in patients undergoing on-pump coronary artery bypass. J Coll Physicians Surg Pak 2020; 30(6): 561–567.

11.

Ozgunay

Ozsin

Ustundag

, et al. The effect of continuous ventilation on thiol-disulphide homeostasis and albumin-adjusted ischemia-modified albumin during cardiopulmonary bypass. Braz J Cardiovasc Surg 2019; 34(4): 436–443.

12.

Gunduz

Mentese

Turedi

, et al. Serum ischemia-modified albumin increases in critical lower limb ischemia. Emerg Med J 2008; 25: 351–353.

13.

Lippi

Montagnana

Salvagno

, et al. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007; 45(2): 261–262.

14.

Izquierdo-Porrera

Gardner

Bradham

, et al. Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication. J Vasc Surg 2005; 41(4): 625–630.

15.

Long

Modrall

Parker

, et al. Correlation between ankle-brachial index, symptoms, and health-related quality of life in patients with peripheral vascular disease. J Vasc Surg 2004; 39(4): 723–727.

16.

McDermott

Liu

Greenland

, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292(4): 453–461.

17.

McDermott

Guralnik

Ferrucci

, et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 2008; 117(19): 2484–2491.

18.

Don

Kaysen

. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004; 17(6): 432–437.

19.

Peters

Jr Stewart

. Albumin research in the 21st century. Biochim Biophys Acta 2013; 1830(12): 5351–5353.

20.

Mikhailidis

Ganotakis

. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7(3): 125–137.

21.

Gresele

Deckmyn

Huybrechts

, et al. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol 1984; 33(13): 2083–2088.

22.

Nelson

Liao

Sharrett

, et al. Serum albumin level as a predictor of incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 2000; 151(5): 468–477.

23.

Dong

Rundek

, et al. Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes: Northern Manhattan study. Stroke 2014; 45(4): 973–978.

24.

Shirasu

Miyata

Nishiyama

, et al. Useful predictors for critical limb ischemia in severely ischemic limbs. Int Angiol 2016; 35(5): 460–468.

25.

Harrison

Griendling

Landmesser

, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91(3A): 7A–11A.

26.

Demirtas

Karabag

Demirtas

. Ischemic modified albumin predicts critical coronary artery disease in unstable angina pectoris and non-ST-elevation myocardial infarction. J Clin Med Res 2018; 10(7): 570–575.

27.

Uslu

Kucuk

Balta

, et al. The relation between ischemia modified albumin levels and carotid intima media thickness in patients with rheumatoid arthritis. Int J Rheum Dis 2019; 22(1): 32–37.

28.

Adly

AAM

ElSherif

NHK

Ismail

EAR

, et al. Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major. Redox Rep 2017; 22(6): 430–438.

29.

Wei

Hong

, et al. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo) 2011; 66(10): 1677–1680.

30.

Falkensammer

Frech

Duschek

, et al. Prognostic relevance of ischemia-modified albumin and NT-proBNP in patients with peripheral arterial occlusive disease. Clin Chim Acta 2015; 438: 255–260.